Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45+0.05 (+11.52%)
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Aprea Therapeutics cash
Cash and short-term investments held at the end of each period.
Aprea Therapeutics's cash was $41.23M at Jun 30, 2026. For fiscal 2025 it was $14.60M, down 36.2% from the year before. The highest annual figure on record is $130.09M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.60M | -36.2% |
| FY2024 | Dec 31, 2024 | $22.89M | +5.7% |
| FY2023 | Dec 31, 2023 | $21.65M | -24.8% |
| FY2022 | Dec 31, 2022 | $28.79M | -45.8% |
| FY2021 | Dec 31, 2021 | $53.08M | -40.4% |
| FY2020 | Dec 31, 2020 | $89.02M | -31.6% |
| FY2019 | Dec 31, 2019 | $130.09M | +98.1% |
| FY2018 | Dec 31, 2018 | $65.68M | +169.1% |
| FY2017 | Dec 31, 2017 | $24.40M | +78.6% |
| FY2016 | Dec 31, 2016 | $13.67M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $41.23M | +149.4% |
| Q1 FY2026 | Mar 31, 2026 | $46.47M | +141.1% |
| Q4 FY2025 | Dec 31, 2025 | $14.60M | -36.2% |
| Q3 FY2025 | Sep 30, 2025 | $13.72M | -47.7% |
| Q2 FY2025 | Jun 30, 2025 | $16.53M | -42.4% |
| Q1 FY2025 | Mar 31, 2025 | $19.28M | -40.5% |
| Q4 FY2024 | Dec 31, 2024 | $22.89M | +5.7% |
| Q3 FY2024 | Sep 30, 2024 | $26.25M | +3.5% |
| Q2 FY2024 | Jun 30, 2024 | $28.69M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $32.37M | +4.4% |
| Q4 FY2023 | Dec 31, 2023 | $21.65M | -24.8% |
| Q3 FY2023 | Sep 30, 2023 | $25.35M | -23.4% |
| Q2 FY2023 | Jun 30, 2023 | $27.69M | -29.1% |
| Q1 FY2023 | Mar 31, 2023 | $31.00M | -35.0% |
| Q4 FY2022 | Dec 31, 2022 | $28.79M | -45.8% |
| Q3 FY2022 | Sep 30, 2022 | $33.11M | -46.1% |
| Q2 FY2022 | Jun 30, 2022 | $39.06M | -44.0% |
| Q1 FY2022 | Mar 31, 2022 | $47.65M | -38.6% |
| Q4 FY2021 | Dec 31, 2021 | $53.08M | -40.4% |
| Q3 FY2021 | Sep 30, 2021 | $61.43M | -39.3% |
| Q2 FY2021 | Jun 30, 2021 | $69.80M | -38.2% |
| Q1 FY2021 | Mar 31, 2021 | $77.62M | -36.6% |
| Q4 FY2020 | Dec 31, 2020 | $89.02M | -31.6% |
| Q3 FY2020 | Sep 30, 2020 | $101.15M | +93.3% |
| Q2 FY2020 | Jun 30, 2020 | $112.86M | +85.0% |
| Q1 FY2020 | Mar 31, 2020 | $122.51M | +86.5% |
| Q4 FY2019 | Dec 31, 2019 | $130.09M | +98.1% |
| Q3 FY2019 | Sep 30, 2019 | $52.33M | +323.6% |
| Q2 FY2019 | Jun 30, 2019 | $60.99M | +150.0% |
| Q1 FY2019 | Mar 31, 2019 | $65.68M | +380.7% |
| Q4 FY2018 | Dec 31, 2018 | $65.68M | – |
| Q3 FY2018 | Sep 30, 2018 | $12.35M | – |
| Q4 FY2017 | Dec 31, 2017 | $24.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.67M | – |
See a number that looks wrong?